A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects

Healthy Subjects Clinical Trial

Official title:

A Four-part, Single-center, Open-label, Phase I Clinical Study to Evaluate the Drug-Drug Pharmacokinetic Interaction Between DBPR108 at Steady-state and Metformin Hydrochloride/Glibenclamide/Valsartan/ Simvastatin in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04859452
• Other study ID #: HA1118-CSP-010
• Status: Completed
• Phase: Phase 1
• Start date: May 26, 2021
• Est. completion date: July 9, 2021

Study information

• Verified date: April 2021
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a four-part, single-center, open-label, single-sequence crossover phase I clinical study to characterize the Drug-Drug Interaction (DDI) potential of DBPR108 at steady-state with Metformin hydrochloride, Glibenclamide, Valsartan, or Simvastatin in Healthy Subjects. This study also aims to evaluate the safety and tolerability of DBPR108 in the presence of Metformin hydrochloride, Glibenclamide, Valsartan, or Simvastatin.

Description:

DBPR108 is a potent dipeptidylpeptidase-4 inhibitor. This study will be run in four parts to characterize the Drug-Drug Interaction (DDI) potential of DBPR108 with the expected concomitant drugs (Metformin hydrochloride, Glibenclamide, Valsartan, Simvastatin) in Healthy Subjects. Each part of this study consists of a screening period (Day -14 to Day -1), a baseline period (Day -1), a treatment period (Day 1 to Day 9), and a follow-up visit on Day 15. Approximately 14 subjects will be enrolled in each part of this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: July 9, 2021
• Est. primary completion date: July 3, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions;

• 18 years to 45 years (inclusive), male or female;

• Male subjects weight =50 kg and female subjects weight =45 kg. Body mass index (BMI) :

18-30 kg/m2 (inclusive) (BMI= weight (kg)/height 2 (m2));

• Subjects (including partners) are willing to use effective contraceptives from screening to the 6 months after the last dose administration;

• Be judged to be in good health by the investigator, based on the physical examination, vital sign examination, 12-lead electrocardiogram (ECG) examination and laboratory examination;

Exclusion Criteria:

• Subjects who have a history of allergic conditions (such as asthma, urticaria), or have a history of allergy to two or more drugs or food, or may be allergic to the test drug and the related compounds;

• Have a history of severe diseases, such as cardiovascular, respiratory, liver, gastrointestinal, endocrine, hematologic, mental/nervous systems diseases within 1 year prior to screening;

• Subjects who have previously undergone surgery that may affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or who have a scheduled surgical plan during the study period;

• Use of any prescription drug, over-the-counter drug, or herbal medicine within 2 weeks prior to screening;

• Drug abuse, or positive urine drug screen at screening;

• Smoking more than 5 cigarettes per day within 3 months prior to screening;

• Average alcohol intake is more than 28g alcohol (male) or 14g (female) per week (14g ˜ 497mL beer, or 44mL spirits with low alcohol content, or 145mL wine) within the 3 months prior to screening, or taking any alcohol within 48 hours before dosing, or a positive ethanol breath test at screening;

• Consumption of grapefruit juice, Methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) within 48 hours before the administration, or have strenuous exercise, or have other factors affecting drug absorption, distribution, metabolism, excretion, etc;

• Participation in another clinical trial within 3 months before screening;

• Blood donation (or blood loss) =400 mL, or receiving whole blood transfusions or erythrocyte suspension transfusions within 3 months prior to the screening;

• The patients who have undergone comprehensive inspection with any significant clinical significant in physical examination (vital signs, physical examination), routine laboratory examination (blood routine, blood biochemical examination, urine routine), chest X-ray (anteroposterior), abdominal B (liver, bile, pancreas, spleen and kidney) and other examinations, as judged by the investigator;

• Have a positive test result of hepatitis B surface antigen, hepatitis C antibody, anti-human immunodeficiency virus antibody or anti-Treponema pallidum specific antibody;

• A pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial.;

• Not suitable for this study as judged by the investigator;

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• DBPR108 tablets
Drug: DBPR108, tablet, oral
• Metformin hydrochloride tablets
Drug: Metformin hydrochloride, tablet, oral
• Glibenclamide tablets
Drug: Glibenclamide, tablet, oral
• Valsartan Capsules
Drug: Valsartan, capsule, oral
• Simvastatin tablets
Drug: Simvastatin, tablet, oral

Locations

Country	Name	City	State
China	First Affiliated Hospital of Soochow University	Suzhou

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The pharmacokinetic parameters of Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid and DBPR108	Peak Plasma Concentration (Cmax)	Day 1 to Day 9
Primary	The pharmacokinetic parameters of Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid and DBPR108	Area under the plasma concentration versus time curve (AUC)	Day 1 to Day 9
Secondary	The pharmacokinetic parameters	The pharmacokinetic parameters (Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid, DBPR108) : Tmax	Day 1 to Day 9
Secondary	The pharmacokinetic parameters	The pharmacokinetic parameters (Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid, DBPR108) : t1/2	Day 1 to Day 9
Secondary	The pharmacokinetic parameters	The pharmacokinetic parameters (Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid, DBPR108) : Vz/F	Day 1 to Day 9
Secondary	The pharmacokinetic parameters	The pharmacokinetic parameters (Metformin, Glibenclamide, Valsartan, Simvastatin, Simvastatin acid, DBPR108) : CL/F	Day 1 to Day 9
Secondary	The number of volunteers with adverse events as a measure of safety and tolerability	The number of volunteers with adverse events as a measure of safety and tolerability	Day 1 to Day 15